CICC
China’s CICC raises $650m for biomedical fund
CICC Capital has reached a second close of RMB4.2 billion ($650 million) on its latest healthcare fund - the first in China to receive fast-track approval for its role in addressing COVID-19.
Carlyle leads $123m Series D for China's Abbisko
The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.
Eastern Bell, Hidden Hill join $512m China air cargo deal
Eastern Bell Capital and Hidden Hill Capital, the private equity arm of warehousing and logistics player GLP, have participated in a RMB3.35 billion ($512 million) funding round for the freight business of China Southern Airlines.
Sinovation's consulting unit hits $1b valuation with Series C
AInnovation, an artificial intelligence (AI) consulting business established by Sinovation Ventures, has joined the ranks of China’s AI unicorns following a Series C round of funding.
China's Yonghui gets $153m for fresh produce spin-out
Tencent Holdings and CICC Capital have led a RMB1 billion ($153 million) round for Caishixian, a B2B supply chain platform incubated by Yonghui Superstores, a leading Chinese supermarket chain.
China's Chang Guang Satellite raises $376m
Chang Guang Satellite Technology, a China-based commercial satellite developer, has raised RMB2.46 billion ($376 million) in pre-IPO funding. It is the largest-ever funding round in China’s commercial aerospace industry.
JD Health targets largest Chinese PE-backed IPO in two years
JD Health, a Chinese online-to-offline healthcare business that raised around $1.9 billion from private investors after it spun out from JD.com, is looking to raise HK$26.9 billion ($3.48 billion) in its Hong Kong IPO.
PE-backed Lufax follows $2.3b US IPO with weak debut
Online lending and wealth management platform Lufax raised $2.36 billion in the largest US IPO by a PE-backed Chinese company so far this year but endured a difficult first day of trading.
China biotech player Genecast raises $149m Series E
Genecast Biotechnology, a Chinese gene sequencing and precision diagnostics company, has closed a RMB1 billion ($149 million) Series E funding round led by China Structural Reform Fund.
Chinese self-heating hotpot start-up gets $50m Series C
Zihaiguo, a Chinese start-up best-known for its line of self-heating hotpot products, has raised a $50 million Series C round led by CICC Capital at a valuation of $500 million.
China O2O medicine platform raises $150m
Chinese online-to-offline (O2O) medicine retailer Dingdang Kuaiyao has raised RMB1 billion ($150 million) in an extended Series B round featuring Dragon Gate Investment Partners.
CPE leads $224m round for China cancer diagnostics business
3D Diagnostic, a diagnostics spinout from Chinese tumor immunotherapy specialist 3D Medicines, has raised RMB1.5 billion ($224 million) in funding led by CPE, formerly known as CITIC Private Equity.
PE-backed Chinese fintech player Lufax files for US listing
Lufax, a Chinese online lending and wealth management platform valued at $39.4 billion following its most recent private funding round, has filed for an IPO in the US.
China's Hinova Pharma raises $147m Series C
Hinova Pharma, a Chinese drug developer has raised RMB1 billion ($147 million) in Series C funding from Shenzhen Investment, Hong Kong-listed Tigermed, Huarong Rongde Asset Management, CCB Internationa, and a fund run by Sinopharm Group and CICC Capital.
PE-backed JD Health files for Hong Kong IPO
JD Health, the healthcare unit of Chinese e-commerce giant JD.com, has filed for Hong Kong IPO. The company’s backers include Hillhouse Capital, CPE, CICC Capital, and Baring Private Equity Asia.
Vision Fund leads $319m round for China's XtalPi
China and US-based artificial intelligence-enabled drug development platform XtalPi has raised $319 million in Series C funding led by SoftBank Vision Fund, the investment arm of insurer PICC Group, and Morningside Venture Capital.
China healthcare big data player LinkDoc raises $102m
LinkDoc Technology, a Chinese healthcare big data company, has raised RMB700 million ($102 million) in an extended Series D round from CICC Capital, Youshan Capital, and iFOF, a fund-of-funds launched by CBC Capital and the Tianjin government.
China mixed reality player Nreal secures $40m Series B
Nreal, a Chinese manufacturers of advanced virtual reality glasses that resemble normal sunglasses, has raised $40 million in Series B funding led by local video sharing platform Kuaishou.
Chinese rocket developer i-Space raises $173m
Chinese commercial rocket developer i-Space - also known as Interstellar Glory Space - has raised a RMB1.2 billion ($173 million) Series B round led by State-owned Beijing Financial Street Capital Operation Center.
China's Vision Medicals raises $28m
CDH Investment has led a RMB200 million ($28 million) Series B round for Guangzhou-based precision diagnosis and gene sequencing company Vision Medicals.
Huagai leads $43m round for China antibiotics developer
China-focused private equity firm Huagai Capital has a led a RMB300 million ($43 million) Series D round for antibiotics developer MicuRX Pharmaceuticals.
Deal focus: Haihe's biotech out-licensing ambition
Warburg Pincus picked Haihe Pharmaceutical as its first bet on innovative drug development in China, having been convinced by the company's mature portfolio and international expansion plans
Chinese online fresh produce retailer Miss Fresh gets $495m
Chinese online grocer Miss Fresh has raised $495 million in funding - said to be the largest private round ever seen in the country's fresh produce industry.
Warburg Pincus leads Series B for China's Haihe Pharmaceutical
Warburg Pincus has led a RMB1.2 billion ($171 million) Series B round for Haihe Pharmaceutical, a Chinese cancer drug developer that currently has four treatments in stage-three clinical trials or beyond.